Human Milk Oligosaccharides Inhibit Norovirus Diseases

  • Author:
  • Published: 29 May 2020
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Journal of Biotechnology/Elsevier
thumbnail image: Human Milk Oligosaccharides Inhibit Norovirus Diseases

Norovirus infections cause severe gastroenteritis in millions of people every year. Breast-fed babies are less likely than bottle-fed infants to get norovirus infections. This protective effect has been linked to human milk oligosaccharides (HMOs). HMOs are complex sugar molecules that are only found in breast milk. Excluding water, they are the third most abundant constituent of human milk after fats and lactose. More than 200 structurally distinct HMOs have been identified. They are important for the development of the intestinal flora. The most abundant HMO is 2'-fucosyllactose (2′'FL).

A norovirus infection requires the recognition of histo-blood group antigens (HBGAs). HMOs can mimic the structures of these natural receptors for the virus on human cells, coat the virus, and prevent it from interacting with its targets. This has been demonstrated for 2'-FL and 3-fucosyllactose (3-FL). Therefore, HMO supplements could help to prevent norovirus infections.

It is possible to produce industrial quantities of 2'-FL by fermentation, and this HMO is already used as a supplement in infant formula products. However, the industrial production of more complex HMOs, which mimic the virus receptors even more closely, is challenging.

Katja Parschat, Jennewein Biotechnologie GmbH, Rheinbreitbach, Germany, and colleagues have developed a large-scale fermentation process for the production of the complex fucosylated HMO lacto-N-fucopentaose I (LNFP I, pictured) in Escherichia coli BL21(DE3) cells.

Highly-purified LNFP I was turned into HBGA-like oligosaccharides by enzymatic conversion. The resulting oligosaccharides were tested in norovirus inhibition assays. The team found that a combination of simple and complex fucosylated structures is more likely to prevent norovirus infections. Further studies are required to determine the best combination of simple and complex fucosylated HMOs for the prevention of norovirus infections.




Article Views: 874

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

Magazine of Chemistry Europe (16 European Chemical Societies)published by Wiley-VCH